Addressing these questions would help us depict a better image for how TRIM26 acts as a dual player in tumorigenesis and as a potential drug target for future development of anti-cancer therapies, at least for gliomas, CRC, bladder cancer and melanoma. This evidence concerns the gene TRIM26 and urinary bladder carcinoma.